A total of 278 eligible patients (222 male; 53.6 ± 11.6 years) were enrolled during the study period (Figure 1), 208 (74.8%) with GPC-3 positive HCC and 70 (25.2%) with GPC-3 negative HCC. The gene discussed is GPC3; the disease is hepatocellular carcinoma.